FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer By Ogkologos - February 27, 2025 472 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR How to Improve Cancer-Related Fatigue Using Exercise: Expert Perspectives June 21, 2023 Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond... November 30, 2021 Survey results reveal attitudes towards cancer screening during the pandemic July 16, 2021 Saving Time for Patients and Improving Well-Being Through Mindfulness and Fitness:... October 23, 2023 Load more HOT NEWS Silence Speaks Volumes Shorter Course of Radiation Is Effective, Safe for Some with Early-Stage... Selpercatinib Slows Progression of RET-Positive Lung, Medullary Thyroid Cancers For Esophageal Cancer, Immunotherapy Likely to Play Larger Role
